Kairos Pharma Ltd(KAPA) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
September 11 at 5:59 PM ET (Korea 9/12 06:59)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -1.95 | Insider Own | 37.2% | Shs Outstand | 3.1M | Perf Week | 5.27% |
| Market Cap | 0.01B | Forward P/E | - | EPS next Y | -53.03% | Insider Trans | - | Shs Float | 2.1M | Perf Month | -29.18% |
| Enterprise Value | 0.00B | PEG | - | EPS next Q | -0.56 | Inst Own | 4.08% | Short Float | 2.7% | Perf Quarter | -45.19% |
| Income | -0.01B | P/S | - | EPS this Y | -10% | Inst Trans | - | Short Ratio | 0.18 | Perf Half Y | -58.14% |
| Sales | 0.00B | P/B | 1.28 | EPS next 5Y | -22.76% | ROA | -104.32% | Short Interest | 0.06M | Perf YTD | -64.63% |
| Book/sh | 1.37 | P/C | 2.26 | EPS past 3/5Y | -53.5% -29.28% | ROE | -113.96% | 52W High | -86.5% ($13.02) | Perf Year | -86.05% |
| Cash/sh | 0.78 | P/FCF | - | Sales past 3/5Y | - | ROIC | -138.51% | 52W Low | 16.42% ($1.51) | Perf 3Y | - |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 11.64% | Gross Margin | - | Volatility(W/M) | 9.21% 9.14% | Perf 5Y | - |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 0.19 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 11.98 | EPS Q/Q | 21.56% | Profit Margin | - | RSI (14) | 42.89 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 11.98 | Sales Q/Q | - | SMA20 | -4.74% ($1.85) | Beta | 1.4 | Target Price | $49 |
| Payout | - | Debt/Eq | 0 | Earnings | 2026/09/02 | SMA50 | -18.39% ($2.16) | Rel Volume | 0.1 | Prev Close | $1.68 |
| Employees | 4 | LT Debt/Eq | 0 | EPS/Sales Surpr. | - | SMA200 | -54.01% ($3.83) | Avg Volume(3M) | 0.33M | Price | $1.76 |
| IPO | 2024/9/16 | Option/Short | No/Yes | Trades | 360 | Volume | 31,548 | Change | 4.64% |
Company
KAPA is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.
🧬 Kairos Pharma is a clinical-stage biotech focused on developing anticancer drugs that target cancer cells' drug resistance and immune evasion mechanisms. ENV-105, an antibody that blocks CD105 to overcome resistance, is being developed in castration-resistant prostate cancer (Phase 2) and EGFR-mutant lung cancer (Phase 1), while KROS-101, a small molecule that acts as a GITR ligand, is being developed as a differentiated immuno-oncology candidate at the preclinical stage.
Over the past 1 year, on the lower side
86% below its 1-year high.
KAPA has weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Growth has stalled
Earnings are expected to grow by -10.0% this year.
Tap to view numbers
The price looks about right
Trading at - times earnings.
Tap to view numbers
Results came in about as expected
Slight tendency to miss estimates
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Tap to view numbers
Dividends are hard to expect
This stock does not pay dividends
Ownership looks stable
Institutions hold 4.1%.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
VXF 0.00%It ranks #4 in the industry
Based on market cap of $6M.
KAPA $6M PER -
VRTX $131B PER 30.0
REGN $80B PER 19.3
ARGX $62B PER 37.5
FAQ
What kind of company is KAPA?
KAPA belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of KAPA?
The market cap of KAPA is approximately $6M, ranking 5,643 within its sector.
What is the 52-week high and low for KAPA?
KAPA has recorded a 52-week high of $13.02 and a low of $1.51.
